Development of a precipitation-resistant solution formulation to increase in vivo exposure of a poorly water-soluble compound

International Journal of Pharmaceutics
Lori BurtonXiaohang Shen

Abstract

In vitro and in vivo investigations were conducted to develop a suitable formulation for early toxicology and clinical studies of ((R)-7-(3,4-dichlorophenyl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidin-6-yl)((S)-2-(4-fluorophenyl)pyrrolidin-1-yl)methanone (Compound A), a nonionizable and poorly water-soluble compound that selectively inhibits the ultrarapid potassium current (IKur) and is intended for the treatment of arrhythmia. Various nonaqueous solution formulations were evaluated, in vitro, for ability to prevent or delay precipitation of Compound A from solution following dilution with water. The plasma exposures of precipitation-resistant solutions, non precipitation-resistant solutions, and aqueous suspensions were then compared in rats, dogs, and/or humans. The data indicated that a solubilized, precipitation-resistant formulation achieved the highest plasma concentrations in all species and also improved dose proportionality, particularly in rats. Development of such formulations may be highly valuable for achieving in vivo blood levels often required for successful toxicological and early clinical evaluation of poorly soluble compounds.

References

Jul 1, 1991·Journal of Pharmaceutical Sciences·P C SheenA T Serajuddin
May 1, 1974·Journal of Pharmaceutical Sciences·T Higuchi, M Ikeda
Oct 1, 1993·Journal of Pharmaceutical Sciences·M J SkibicS W Baertschi
Nov 1, 1996·Journal of Pharmaceutical Sciences·R A Rajewski, V J Stella
Jan 1, 1997·Journal of Pharmaceutical Sciences·B C Hancock, G Zografi
Mar 4, 2000·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·L Y Lim, M L Go
Apr 18, 2000·International Journal of Pharmaceutics·G L EngelL L Winneroski
Jun 7, 2000·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·T Gershanik, S Benita
Oct 18, 2000·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·C W Pouton
Mar 22, 2001·Advanced Drug Delivery Reviews·D Hörter, J B Dressman
May 7, 2002·Journal of Controlled Release : Official Journal of the Controlled Release Society·Kohsaku KawakamiKazuyoshi Masuda
Jan 16, 2003·International Journal of Pharmaceutics·Sang-Chul Shin, Jin Kim
Oct 31, 2003·Critical Reviews in Therapeutic Drug Carrier Systems·Sundeep Sethia, Emilio Squillante
Nov 7, 2003·Journal of Pharmaceutical Sciences·Ping GaoMichael J Hageman
Apr 15, 2004·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·R Neslihan Gursoy, Simon Benita
Sep 1, 2004·International Journal of Pharmaceutics·Anshuman A AmbikeAnant Paradkar
Jan 1, 2005·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Anders Bach NielsenClaus Larsen
May 24, 2005·International Journal of Pharmaceutics·Hye-Sun GwakHoo-Kyun Choi
Jun 11, 2005·Pharmaceutical Research·Anshuman A AmbikeAnant Paradkar
Sep 24, 2005·Pharmaceutical Research·Shamkant L ShimpiAnant Paradkar
Jun 27, 2006·The AAPS Journal·Xue-Qing ChenOlafur S Gudmundsson
Oct 4, 2006·Expert Opinion on Drug Metabolism & Toxicology·Seshadri Neervannan
Jul 31, 2007·International Journal of Pharmaceutics·Ping Li, Luwei Zhao
Sep 25, 2007·Journal of Controlled Release : Official Journal of the Controlled Release Society·Rebecca L CarrierImran Ahmed
Feb 27, 2008·International Journal of Pharmaceutics·Wei-Guo DaiZhengyu Deng
Sep 17, 2008·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Adwoa O NornooRachel Reed
Dec 2, 2008·Drug Development and Industrial Pharmacy·Hongfei WuYulian Zhang
Aug 28, 2009·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yong-Mei YinDae-Duk Kim
Oct 14, 2009·Journal of Controlled Release : Official Journal of the Controlled Release Society·Eugene R Cooper
Nov 26, 2009·Drug Development and Industrial Pharmacy·Kalle SigfridssonMarie Strimfors
Aug 6, 2011·Journal of Pharmaceutical and Biomedical Analysis·S ChandranK Raghavan

❮ Previous
Next ❯

Citations

Sep 12, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Walter Ferreira da Silva JúniorÁdley Antonini Neves de Lima

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.